GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cell Source Inc (OTCPK:CLCS) » Definitions » Other Current Assets

Cell Source (Cell Source) Other Current Assets : $0.25 Mil (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Cell Source Other Current Assets?

Cell Source's other current assets for the quarter that ended in Sep. 2023 was $0.25 Mil.

Cell Source's quarterly other current assets increased from Mar. 2023 ($0.10 Mil) to Jun. 2023 ($0.34 Mil) but then declined from Jun. 2023 ($0.34 Mil) to Sep. 2023 ($0.25Mil).

Cell Source's annual other current assets increased from Dec. 2020 ($0.21 Mil) to Dec. 2021 ($0.22 Mil) declined from Dec. 2021 ($0.22 Mil) to Dec. 2022 ($0.19 Mil).


Cell Source Other Current Assets Historical Data

The historical data trend for Cell Source's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cell Source Other Current Assets Chart

Cell Source Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.09 0.21 0.22 0.19

Cell Source Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.19 0.10 0.34 0.25

Cell Source Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Cell Source Other Current Assets Related Terms

Thank you for viewing the detailed overview of Cell Source's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Cell Source (Cell Source) Business Description

Traded in Other Exchanges
N/A
Address
57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. Its other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation.
Executives
George Verstraete director 341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Darlene Soave director, 10 percent owner 341 LAKEWOOD DRIVE, BLOOMFIELD HILLS MI 48304
Yair Reisner 10 percent owner
Yoram Drucker director 31 DOV SADAN ST., JERUSALEM L3 97844
Dennis M Brown director 100 SAN MATEO DR, MENLO PARK CA 94025
Itamar Shimrat director, officer: CEO and CFO C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
David Zolty director C/O CELL SOURCE, INC., 65 YIGAL ALON STREET, TEL AVIV L3 67433
Benzion Abraham Friedman director, 10 percent owner C/O CELL SOURCE INC, 65 YIGALL ALON STREET, TEL AVIV L3 67433

Cell Source (Cell Source) Headlines